# Peptide Drugs in Gastrointestinal Tumors: Integrating Targeting, Delivery, and Therapeutic Actions for Synergistic Strategies

**Authors:** Qian Ouyang, Guifang Wu, Anyi Chen, Rui Zhang, Shuai Xiao, Dong Guo, Qi Zhang, Chaojun Yan, Xing-Zhen Chen, Jingfeng Tang, Hao Lyu

PMC · DOI: 10.3390/biom16030456 · Biomolecules · 2026-03-18

## TL;DR

Peptide drugs show promise for treating gastrointestinal cancers by offering targeted delivery and multiple therapeutic effects.

## Contribution

The paper systematically reviews the progress and potential of peptide drugs in gastrointestinal tumor treatment.

## Key findings

- Peptide drugs can specifically target tumor receptors for precise delivery.
- They interfere with tumor signal transduction, metabolism, and immune regulation.
- Peptide drugs offer advantages like biocompatibility and low immunogenicity.

## Abstract

Gastrointestinal malignant tumors account for approximately one-third of global cancer-related deaths, primarily including colorectal, gastric, pancreatic ductal adenocarcinoma, and hepatocellular carcinomas. These tumors have a high incidence, are often asymptomatic, and are prone to metastasis and recurrence, posing a significant public health burden. Although traditional methods such as radiotherapy and chemotherapy can delay disease progression, their nonspecific effects often lead to severe side effects and drug resistance, resulting in limited efficacy. Therefore, developing novel treatment strategies with high target specificity and favorable biological safety is a critical scientific issue in this field. Peptide drugs offer advantages such as good biocompatibility, low immunogenicity, diverse structures, and ease of modification, collectively demonstrating unique potential for tumor treatment. They can not only achieve precise delivery by specifically recognizing tumor receptors but can also directly interfere with signal transduction, metabolism, and immune regulation, producing multi-target antitumor effects. This article systematically reviews the research progress of peptide drugs in gastrointestinal tumors, focusing on their molecular mechanisms, delivery modification strategies, and the latest applications. It also summarizes the challenges and future directions for clinical translation, providing a theoretical foundation and future perspectives for the precise treatment of gastrointestinal tumors and the design of new drugs.

## Linked entities

- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184)

## Full-text entities

- **Diseases:** metastasis (MESH:D009362), Gastrointestinal Tumors (MESH:D005770), colorectal, gastric, pancreatic ductal adenocarcinoma (MESH:D021441), hepatocellular carcinomas (MESH:D006528), cancer (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024651/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024651/full.md

## References

238 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024651/full.md

---
Source: https://tomesphere.com/paper/PMC13024651